Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 1.00 |
| ▸ | F2 | P00734 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3181722 | 1.00 | F10 (1.00) | F10F2 | |
| SCHEMBL3181714 | 1.00 | F10 (1.00) | F10F2 | |
| SCHEMBL12036209 | 1.00 | F10 (1.00) | F10F2 | |
| SCHEMBL6032855 | 1.00 | F10 (1.00) | F10F2 | |
| SCHEMBL3192216 | 1.00 | F10 (1.00) | F10F2 | |
| Hydrochloric Acid SCHEMBL1504050 | 0.99 | F10 (0.99) | F10F2 | |
| Hydrochloric Acid SCHEMBL1504013 | 0.99 | F10 (0.99) | F10F2 | |
| SCHEMBL3188583 | 0.94 | F10 (0.89) | F10F2 | |
| SCHEMBL3188580 | 0.94 | F10 (0.89) | F10F2 | |
| SCHEMBL3193325 | 0.94 | F10 (0.88) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266991-A2 | Process for producing thiazole derivative | Daiichi Sankyo Company, Limited (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266992-A2 | Process for producing thiazole derivative | Daiichi Sankyo Company, Limited (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-20100076192-A1 | PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| US-7678910-B2 | Process for producing 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]Pyridine-2-carboxylic acid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-03-16 | — | — | US | disclosed |
| US-20090192313-A1 | PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-7547786-B2 | 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid; intermediate for compound which exhibits an inhibitory action on an activated coagulation factor X, and which is thus useful as a preventive/therapeutic drug for thrombus-related diseases | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-06-16 | — | — | US | disclosed |
| US-20070135476-A1 | Process for producing thiazole derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1683800-A1 | PROCESS FOR PRODUCING THIAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076192-A1 | PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID | NOX4, NOX5, NOS2 | F10 1072/4885F2 1340/4885 |
| US-20090192313-A1 | PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID | PAH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL4 | F10 388/4885F2 1156/4885 |
| US-20070135476-A1 | Process for producing thiazole derivative | TALDO1, CYP3A4, DHPS | F10 4433/4885F2 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.